Literature DB >> 11701780

Disease modifying treatment in multiple sclerosis.

G N Fuller1, I Bone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11701780      PMCID： PMC1765573          DOI： 10.1136/jnnp.71.suppl_2.ii20

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  8 in total

1.  The cost of delaying treatment in multiple sclerosis: what is lost is not regained.

Authors:  S R Schwid; C T Bever
Journal:  Neurology       Date:  2001-06-26       Impact factor: 9.910

2.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

Authors:  L D Jacobs; R W Beck; J H Simon; R P Kinkel; C M Brownscheidle; T J Murray; N A Simonian; P J Slasor; A W Sandrock
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

3.  Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis.

Authors:  R B Forbes; A Lees; N Waugh; R J Swingler
Journal:  BMJ       Date:  1999-12-11

Review 4.  Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease?

Authors:  G Rice; G Ebers
Journal:  Arch Neurol       Date:  1998-12

5.  Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost?

Authors:  J Bryant; A Clegg; R Milne
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

6.  Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results.

Authors:  D K Li; G J Zhao; D W Paty
Journal:  Neurology       Date:  2001-06-12       Impact factor: 9.910

7.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

Authors:  K P Johnson; B R Brooks; J A Cohen; C C Ford; J Goldstein; R P Lisak; L W Myers; H S Panitch; J W Rose; R B Schiffer
Journal:  Neurology       Date:  1995-07       Impact factor: 9.910

8.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422
  8 in total
  1 in total

Review 1.  Favorable outcome of early treatment of new onset child and adolescent migraine-implications for disease modification.

Authors:  James A Charles; B L Peterlin; Alan M Rapoport; Steven L Linder; Marielle A Kabbouche; Fred D Sheftell
Journal:  J Headache Pain       Date:  2009-06-09       Impact factor: 7.277
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.